On April 23, 2021, Quanterix and WuXi AppTec’s Laboratory Testing Division (LTD) inaugurated the “Joint Laboratory for Biomarker Clinical Analysis” at WuXi AppTec’s headquarters in Shanghai. The event attracted more than 50 guests including Dr. Steve Yang, WuXi AppTec Co-CEO, Mr. Benny Yan, General Manager of Quanterix Asia Pacific Region, and Dr. Shi Jing, WuXi AppTec’s Global Head of Large Molecule Bioanalysis.
The joint lab was established in February of this year. This collaboration aims to expand WuXi AppTec’s biomarker testing services to provide joint solutions to a wider range of customers. Simoa Joint Lab is a collaborative effort by the Bioanalytical Service of WuXi AppTec’s LTD and Quanterix. This facility will leverage Quanterix’ ultra-sensitive Simoa HD-XTM analyzers, consumable resources and technical expertise to advance pre-clinical and clinical research.
The opening session began with remarks by Dr. Steve Yang, Co-CEO of WuXi AppTec. Dr. Yang stated, “First of all, I would like to sincerely thank everyone for attending the opening ceremony of this joint laboratory despite having such busy schedules. It is a leading global joint laboratory established by WuXi AppTec and Quanterix to provide biomarker clinical analysis solutions to customers worldwide. Now that the first batch of biomarker validation has been completed, we hope to empower our global partners in the future to expedite the discovery and development of new medicines for patients globally, so as to realize our vision that every drug can be made and every disease can be treated.”
Opening Ceremony
Quanterix
Mr. Benny Yan, GM of Quanterix Asia Pacific Region addressed the attendees: “It has been a great honor for me to attend this event on behalf of Quanterix. Our company is dedicated to advancing precision medicine. Simoa (Single-molecule Array) technology brings more than just a breakthrough in sensitivity, but more importantly, offers the future applications of non-invasive examinations. Simoa technology is now serving key global research institutions, industry-leading pharmaceuticals, and enabling platforms like WuXi AppTec. With the establishment of this joint lab, we also hope to leverage the strong platform of WuXi AppTec to better serve our global customers with this technology and advance innovation in new drug development.”
WuXi AppTec
Speaking at the event, Dr. Shi Jing, Global Head of WuXi AppTec’s LTD Large Molecule Bioanalysis, said the following: “With platforms like Simoa on board, we will be able to detect biomarkers faster and more accurately in the near future. Our joint lab, combining WuXi AppTec’s bioanalytical team’s 15 years of experience in conducting clinical bioanalytical projects with Quanterix’s advanced technology, boasts the advantage of high sensitivity compared to traditional technologies, and its multi-component and automation levels are the way forward for bio-labs. Going forward, Simoa Joint Lab will offer method development, method transfer, and clinical trial sample analysis, while we will be validating a number of methods for commonly used biomarkers in the near future that can more rapidly facilitate new drug development and address the need for trials.”
Finally, guided by technical experts, the guests visited the joint laboratory and had a further detailed understanding of the HD-XTM analyzer and testing solutions.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,400 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”
